The Pan-Immune-Inflammation Value Predicts the Survival of Patients with ER-positive, HER-2-Negative Metastatic Breast Cancer Treated with CDK4/6 inhibitors | Zendy

AI Assistant Blog Pricing

The Pan-Immune-Inflammation Value Predicts the Survival of Patients with ER-positive, HER-2-Negative Metastatic Breast Cancer Treated with CDK4/6 inhibitors

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.